SANDOZ GROUP AG S/ADR (SDZNY)
SDZNY moved a median of +0.31% 30 minutes after news, and +0.14% by the close. How SDZNY actually reacts to news — the realized, point-in-time move the market made, measured across 74 labeled events over the last three years with zero look-ahead.
SDZNY’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 74 |
| 30-min | +0.31% | 55% | 74 |
| 60-min | +0.26% | 69% | 74 |
| to close | +0.14% | 54% | 72 |
| Middle 50% of SDZNY reactions | -0.24% to +0.57% |
|---|---|
| Median reaction (30-min) | +0.31% |
| Measured reactions | 74 |
Half of all SANDOZ GROUP AG S/ADR news events land between -0.24% and +0.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SDZNY reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 11 | +0.07% | 64% | +0.84% |
| Analyst downgrades | 15 | -0.05% | 47% | +0.06% |
| Coverage initiations | 10 | +0.10% | 50% | -0.09% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how SDZNY ranks against every other measured name →
That’s how SDZNY usually reacts — get an email when it moves on news →Email me when SDZNY moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SDZNY's baseline. Nothing else.
Recent SDZNY events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform | Press release | PR Newswire | -0.06% | -1.07% | |
| Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US | Press release | Business Wire | +0.00% | +0.09% | |
| Sandoz welcomes Quebec government support for Boucherville plant modernization project | Press release | Canada Newswire | +0.03% | +0.05% | |
| Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations | Press release | GlobeNewswire | +0.05% | — | |
| Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter | Press release | GlobeNewswire | -0.07% | +1.66% | |
| Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars | Press release | GlobeNewswire | -0.11% | -0.23% | |
| Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed | Press release | GlobeNewswire | +0.00% | +3.41% | |
| Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications | Press release | GlobeNewswire | +0.35% | -0.16% | |
| Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG | Press release | GlobeNewswire | +0.00% | +2.27% | |
| Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility | Press release | GlobeNewswire | +0.00% | +0.43% | |
| Sandoz reports strong FY 2024 results and Q4 2024 sales | Press release | GlobeNewswire | +2.11% | +2.04% | |
| Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4] | Press release | GlobeNewswire | -2.62% | -1.69% | |
| Francisco Ballester to retire; Peter Stenico appointed President Region International | Press release | GlobeNewswire | +0.00% | +0.44% | |
| Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +1.51% | +1.41% | |
| Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio | Press release | GlobeNewswire | +1.86% | +2.58% | |
| Sandoz reports third-quarter and nine-month 2024 sales | Press release | GlobeNewswire | +0.09% | -0.11% | |
| Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio | Press release | GlobeNewswire | +2.10% | +1.94% | |
| Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market | Press release | GlobeNewswire | -0.41% | -0.07% | |
| Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position | Press release | GlobeNewswire | -0.41% | -0.07% | |
| Sandoz reports second-quarter sales and half-year 2024 results | Press release | GlobeNewswire | +0.40% | +0.30% | |
| Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases | Press release | GlobeNewswire | +0.00% | +0.71% | |
| FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US | Press release | GlobeNewswire | +0.08% | -0.33% | |
| Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio | Press release | GlobeNewswire | +0.23% | +0.92% | |
| Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe | Press release | GlobeNewswire | -0.09% | +0.54% | |
| Sandoz reports first quarter 2024 sales | Press release | GlobeNewswire | +0.00% | -2.04% | |
| Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars | Press release | GlobeNewswire | +0.18% | -0.03% | |
| Sandoz announces nominations to the Board of Directors and leadership change | Press release | GlobeNewswire | -0.09% | -0.68% | |
| Sandoz receives FDA approval for first and only denosumab biosimilars | Press release | GlobeNewswire | +0.11% | +0.14% | |
| Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market | Press release | GlobeNewswire | +0.22% | +0.47% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SDZNY section they belong to.
Where else SDZNY is measured.
SDZNY earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is SANDOZ GROUP AG S/ADR's median reaction calculated?
Every labeled SDZNY news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 74 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of SDZNY's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SDZNY's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.